APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Phase 1
Terminated
- Conditions
- Hepatocellular CarcinomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Apollomics (Australia) Pty. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03655613
- Locations
- ๐ฆ๐บ
Royal Melbourne Hospital, Melbourne, Victoria, Australia
๐ฆ๐บFiona Stanley Hospital, Murdoch, Western Australia, Australia
๐ฆ๐บAfffinity Clinical Research, Perth, Western Australia, Australia
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Phase 1
Completed
- Conditions
- Microsatellite InstabilityMismatch Repair DeficiencyCancer of Unknown Primary SiteSolid Tumor
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Apollomics (Australia) Pty. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03053466
- Locations
- ๐ฆ๐บ
Nucleus Network, Melbourne, Victoria, Australia
๐ฆ๐บChris O'Brien Lifehouse, Camperdown, New South Wales, Australia
๐ฆ๐บLinear Clinical Research, Nedlands, Western Australia, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath